Default company panoramic image
Logo

MiniVax

MiniVax is developing novel solutions for the treatment and prevention of opportunistic fungal and bacterial infections.

  • Stage Product In Development
  • Industry Biotechnology
  • Location New Orleans, LA, USA
  • Currency USD
  • Founded November 2010
  • Employees 10
  • Website minivaxcorp.com

Company Summary

MiniVax is focused on the development of novel solutions for the treatment and prevention of opportunistic fungal infections. Based on its proprietary technology, it is currently developing monoclonal antibody therapeutic and vaccines for Pneumocystis pneumonia (PCP), which is a common opportunistic infection in HIV/AIDS, cancer and transplant patients. MiniVax plans to initiate Phase I clinical trials for the antibody therapy in late 2015.

Team

  • Default avatar
    A. Ray Chaudhuri
    Co-Founder, President and CEO

    Dr. A. Ray Chaudhuri has over a decade of experience in the healthcare industry, both domestic and international. His previous experience includes working in US government at the National Institute of Health (NIH) as both a research scientist and grant award manager, in venture capital as a healthcare specialist, and in various operational, management, and fund raising roles at startup companies such as Actis Biologics, Humurine, and Biological

  • Default avatar
    Martin Preuveneers
    COO

    Dr. Martin Preuveneers has been CEO of two venture-backed biotechnology companies focused on respiratory therapeutics. Prior to that, he held several positions at Glaxo Holdings including Director of International Marketing for respiratory products, in which role he was responsible for global marketing of several multi-billion dollar products (such as Zantac), as well as Director of Marketing and Corporate Director of Business Development.

  • Default avatar
    Jay Kolls
    Co-Founder and Chariman of SAB

    Dr. Jay Kolls is Director of Richard King Mellon Institute for Pediatric Research at the Children's Hospital of Pittsburgh. Previously, he was the Chair of Genetics at Louisiana State University Health Science Center. He is a leader in the fields of mucosal immunology and vaccine research and has received over $20 million in federal funding.

  • Default avatar
    Douglas Carnes
    EVP Corporate Development

    Dr. Doug Carnes joined the pharma industry in 1972 with his first job at Smith & French. He was responsible for US marketing of Tagamet. Since then he started two companies and sold both of them, his last company Immunologix, an antibody platform company, was sold to Intrexon in 2011.

  • Default avatar
    Sue Preston
    SVP of Regulatory Affairs

    Sue Preston has close to 30 years of experience in clinical and regulatory affairs. She spent 8 years at the FDA and then spent 25 years as VP of Regulatory Affairs in companies such as Baxter and Chiron.

  • Default avatar
    Sue Preston
    Senior VP Regulatory Affairs

    Ms. Preston has approx. 30 years of experience in regulatory affairs. She spent 8 years at the FDA and about 25 years as VP of Regulatory Affairs at large biotechs such as Medarex, Baxter, Chiron.

  • Default avatar
    Doug Carnes
    Executive VP of Corporate Development

    Dr. Carnes started his pharma career in 1972 at Smith and French which ultimately became GlaxoSmithKline. He was responsible for the US marketing of Tagamet, one of the first blockbuster drugs. In the last 20 years, he had also started two companies both of which were sold - his last company, Immunologix was sold to Intrexon in 2011.

Advisors

  • Default avatar
    Rogan Giles III, Elizabeth Goldstein (Corporate); Dr. Dean Nakamura (IP)
    Lawyer
    Unconfirmed
    Default avatar
    Robert Romako
    Accountant
    Unconfirmed